An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With Topicort (Desoximetasone) Topical Spray, 0.25% in Pediatric Patients With Plaque Psoriasis.
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Desoximetasone (Primary)
- Indications Plaque psoriasis
- Focus Pharmacodynamics
- Sponsors Taro Pharmaceuticals USA
- 26 Jan 2018 Planned End Date changed from 1 Apr 2019 to 1 Dec 2018.
- 26 Jan 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Nov 2018.
- 16 Mar 2017 Planned End Date changed from 1 Jan 2018 to 1 Apr 2019.